EUVIMEDEUVIMED entdecken
EditorialKommentar

Carvedilol, probably the β‐blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!

Càndid Villanueva iD, Dhiraj Tripathi

Liver International · 2023

DOI: 10.1111/liv.15582 ↗

Kurz gefasst

Editorial in der Zeitschrift Liver International, 2023. Verfasst von Càndid Villanueva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Hypertension, Portal, Propanolamines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-selective β-blockers (NSBBs) are the mainstay long-term therapy for portal hypertension. Numerous randomized-controlled trials and observational studies have established their therapeutic benefit in patients with cirrhosis.1 The efficacy of NSBBs is related to the lowering effect on portal-pressure, which decreases the risk of portal hypertension-related events, particularly variceal bleeding. NSBBs achieve the portal-pressure decreasing effect by reducing the splanchnic blood-flow through a decrease in cardiac-output induced by the β-1 adrenergic blockade and, mainly, because of a splanchnic vasoconstriction induced by an unopposed α-adrenergic activity achieved by the β-2 adrenergic blockade.2 Carvedilol, is a potent NSBB that also antagonizes α-1-adrenergic receptors.2, 3 This activity confers to carvedilol, in addition to its NSBB-effect, intrinsic vasodilatory activity and thus the ability to reduce the increased hepatic resistance that is the first mechanism leading to portal hypertension in cirrhosis.4 However, the vasodilatory activity of carvedilol is not liver selective and also affects the systemic circulation, with potential to reduce arterial pressure. This issue of Liver International publishes a review by Turco et al, nicely detailing the effect of carvedilol on portal hypertension in cirrhosis.3 The paper elegantly summarizes the evidence to suggest that carvedilol can be the NSBBs of choice in cirrhosis. However, some considerations may be useful to precisely quantify this otherwise feasible suggestion. A relevant issue when advising therapy for patients with cirrhosis is to be aware of the disease stage. The progression of cirrhosis from a compensated stage to the development of decompensation determines a markedly declined life expectancy.5 Portal hypertension is the main determinant of the disease progression finally leading to the development of decompensating events.4 A hepatic venous pressure gradient (HVPG) ≥10 mmHg defines clinically significant portal hypertension (CSPH) since decompensation almost never develops until reaching this threshold.1 The development of splanchnic vasodilation and hyperdynamic circulation which worsen portal-hypertension in cirrhosis is progressive during the course of the disease. It is more developed in patients with CSPH than in those with mild-PH (i.e. HVPG between 5 and 10 mmHg) and among patients with CSPH is more accentuated in those who have already developed varices than in those without varices.6 Furthermore, the transition of cirrhosis from compensation to decompensation is linked to an accentuated progression of splanchnic vasodilation and further increment in portal-pressure.7, 8 Heart-rate and cardiac-output progressively increased until end stages of decompensation where a reduction of cardiac compensatory reserve can be detrimental.7, 8 We completely agree with our colleagues that carvedilol may be the NSBB of choice in patients with compensated cirrhosis, but the choice is much more complex and nuanced once decompensation develops. In compensated cirrhosis an increased intra-hepatic vascular resistance constitutes the predominant mechanism of portal hypertension, particularly in the early stages of the disease.4, 6 Carvedilol, can ameliorate such vascular resistance because of its anti-α-adrenergic activity together with an enhancement in the intrahepatic release of NO,3, 9 which results in a more favourable drug profile for compensated patients than that of classical-NSBBs. Carvedilol has greater portal-pressure decreasing effect than classical-NSBBs and may achieve hemodynamic response in previous non-responders to classical-NSBBs.10 The PREDESCI study showed the utility of NSBBs to prevent decompensation in compensated cirrhosis, and provided in addition data suggesting that carvedilol may be particularly effective.11 This double-blind, placebo-controlled, RCT only included compensated patients with CSPH and showed that NSBBs can prevent the evolution of cirrhosis to decompensation mainly by decreasing the risk of developing ascites. The trial showed a non-significant trend towards greater benefit with carvedilol than with propranolol to prevent decompensation, even though carvedilol was only given to previous non-responders to intravenous propranolol in an acute response evaluation.11 Furthermore, despite being used only in potentially poor candidates, carvedilol achieved significantly greater long-term decreases in HVPG than propranolol, which was only used in previous responders, at 12 months (16% ± 3% vs. 10% ± 2%, p = .036) and at 24 months (15% ± 4% vs. 9% ± 3%, p = .048).11 A number of RCTs and meta-analyses have shown that NSBBs, including carvedilol, effectively prevent variceal bleeding in patients with cirrhosis and high-risk varices.2, 12 Recently, a meta-analysis performed with individual participant data, clearly reinforced the utility of carvedilol to prevent decompensation, further showing that carvedilol can improve the survival of patients with compensated cirrhosis.13 Using a competing-risk time-to-event IPD-meta-analysis of RCTs comparing carvedilol with a control group receiving no active therapy (which included placebo or endoscopic variceal ligation (EVL) in patients with high-risk varices), the study showed that the risk of developing decompensation of cirrhosis was lower in patients treated with carvedilol than in controls, reducing such risk by half.13 This was mainly as a result of a significant decrease in the risk of developing ascites favouring carvedilol. More importantly, the risk of death was also significantly decreased with carvedilol as compared with controls (SHR = 0.417, 95% CI = 0.194–0.896, p = .025).13 Altogether, available data indicate that long-term therapy with carvedilol can be clearly useful in patients with compensated cirrhosis and CSPH, who are at high-risk of developing decompensation. This suggests that screening compensated patients for the development of CSPH as the indication to start therapy with carvedilol, actually constitutes a beneficial strategy, which has been recommended in the last Baveno consensus.1 As previously commented, the progression of cirrhosis from compensation to decompensation is linked to progressive splanchnic vasodilation and hyperdynamic circulation with a subsequent increment of portal-pressure.7, 8 Patients with decompensated cirrhosis have much more evident hyperdynamic circulation than compensated patients and also have higher portal-pressure.8 Furthermore, among decompensated patients hyperdynamic circulation and portal-pressure significantly increase in those with more advanced disease.7 Heart-rate and cardiac-output progressively increase until end stages of decompensation where a reduction of cardiac compensatory reserve may develop, which is mainly evident in stressful situations such as infections or acute on chronic liver failure, and which may have a negative impact on survival.14, 15 In this situation, drugs such as NSBBs, by further decreasing cardiac-output might have harmful effects.8 In addition, in this advanced stage non-liver selective vasodilators, such as carvedilol, might worsen peripheral vasodilation and induce arterial hypotension.15, 16 This effect may be detrimental, by increasing in turn renal sodium and water retention, particularly in patients with advanced ascites in whom an upregulated sympathetic nervous system helps to maintain arterial pressure.14-16 Consequently, drugs reducing cardiac-output and drugs inducing systemic vasodilation should be used cautiously in advanced cirrhosis, and carvedilol has the potential to induce both effects. Arterial pressure should be closely monitored in these circumstances.17 Whether non-invasively monitoring CO may help in this situation needs to be clarified.8 On the other hand, the clinical setting where NSBBs are used in decompensated cirrhosis is highly relevant (Figure 1). When used to prevent rebleeding in decompensated patients the addition of NSBBs to EVL significantly reduce the rebleeding risk and improves survival compared to EVL monotherapy, as shown by an IPD-meta-analysis of RCTs.18 However, when used in a more stable setting, such as the prevention of first bleeding in patients with high-risk varices, the benefit with NSBBs is much lower.9 In this setting, another recent IPD-meta-analysis involving only decompensated patients has not shown a benefit on bleeding or survival favouring NSBBs as compared to EVL.19 Whether carvedilol may improve these outcomes in decompensated patients needs still to be clarified. As detailed in the paper by Turco et al in this issue, some observational studies suggest benefits favouring carvedilol in patients with ascites.3 However, other observational studies suggest that carvedilol may be less effective than classical-NSBBs treating patients in the waiting list for liver transplantation.20 No RCT has compared carvedilol versus classical-NSBBs (both in addition to EVL) in patients treated to prevent rebleeding. No RCT has compared carvedilol versus EVL to prevent first variceal bleeding specifically in patients with decompensated cirrhosis, in whom no benefit with classical-NSBBs over EVL has been demonstrated and in whom systemic vasodilatation may be detrimental. In this regard, results of the CALIBRE trial (ISRCTN73887615), which stratified patients according to baseline decompensation, may be valuable. Furthermore, no RCT has investigated the potential utility of carvedilol (or classical-NSBBs) in decompensated patients without varices. It is possible that the judicious use of carvedilol might be useful in decompensated patients. However, the benefits of carvedilol could be negated in patients with advanced decompensation, given their extensive systemic vasodilation. Clearly, all the evidence gaps commented should be filled before universal recommendation of carvedilol in all patients with decompensated cirrhosis. Whether classical NSBBs cautiously titrated to heart rate and arterial pressure are a safer option or conversely whether carvedilol used even more carefully is a better option in decompensated patients still needs to be elucidated. This study has been supported in part by grants from the Instituto de Salud Carlos III (EC08/00087, PI10/01552, PI13/02535, PS09/00485, PI14/00876 and PI15/00066). The CIBERehd is funded by the Instituto de Salud Carlos III (ISCiii). The authors have no conflict of interest with regard to this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalPropanolaminesHumansCarvedilolAdrenergic beta-AntagonistsLiver CirrhosisCarbazoles

Substanzen

CarvedilolAdrenergic beta-AntagonistsPropanolaminesCarbazoles

Autor:innen und Institutionen

  • Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.

ORCID-Profile: Càndid Villanueva

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Villanueva, C., & Tripathi, D. (2023). Carvedilol, probably the β‐blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!. Liver International. https://doi.org/10.1111/liv.15582

Vancouver

Villanueva C, Tripathi D. Carvedilol, probably the β‐blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!. Liver International. 2023. doi:10.1111/liv.15582

BibTeX
@article{Villanueva2023,
  author = {Villanueva, Càndid and Tripathi, Dhiraj},
  title = {Carvedilol, probably the β‐blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!},
  journal = {Liver International},
  year = {2023},
  doi = {10.1111/liv.15582}
}
Kostenlos starten →